Skip to main content
main-content

Diabetes medications


Browse the latest news, expert commentary, and educational content on diabetes medications.


SGLT2 inhibitor use in type 2 diabetes management

Learn about prescribing these medications with guidance from the Improving Diabetes Steering Committee.

  • » A prescribing tool to inform prescribing decisions for SGLT2 inhibitors
  • » SGLT2 inhibitors: Key evidence and implications for clinical practice
  • » Translating SGLT2 inhibitor cardiovascular evidence into practice
  • » This content is intended only for UK healthcare providers and was made possible by educational funding provided by Napp Pharmaceuticals Ltd.

07-30-2021 | SGLT2 inhibitors | News

SGLT2 inhibitors linked to lower mortality rate than sulfonylureas in clinical practice

Use of SGLT2 inhibitors rather than sulfonylureas as an addition to metformin therapy may be associated with a reduced mortality risk for people with type 2 diabetes, suggest real-world study findings.

07-22-2021 | Nephropathy | News

SGLT2 inhibition may improve renal oxygenation

Treatment with the SGLT2 inhibitor dapagliflozin produces acute increases in renal oxygenation in people with type 1 diabetes and albuminuria, say researchers.

07-15-2021 | Glycemic control | News

Early second-line therapy response predicts sustained HbA1c reductions in type 2 diabetes

Early achievement of a glycated hemoglobin (HbA1c) level below 7% is a key factor in maintaining long-term glucose control in people with type 2 diabetes initiating second-line glucose-lowering therapy, DISCOVER study data show.

07-12-2021 | Ethnic groups | News

High CVD cost of ethnic statin prescribing disparities in type 2 diabetes

Reasons for ethnic disparities in statin prescribing in UK residents with type 2 diabetes are not clear, but may result in preventable atherosclerotic cardiovascular disease events, research suggests.

07-09-2021 | COVID-19 | Ask the expert | Article

An update on COVID-19 and diabetes

Stefan Bornstein provides an overview of the current understanding about COVID-19 and diabetes, including medications, vaccines, and the impact of SARS-CoV-2 infection on diabetic ketoacidosis.

07-07-2021 | Immunotherapy | News

Imatinib could slow beta-cell decline in early type 1 diabetes ​

A 6-month course of treatment with the tyrosine kinase inhibitor imatinib may slow the decline in beta-cell function in people with newly diagnosed type 1 diabetes, but the effect is not sustained in the longer term, phase 2 study findings indicate.

07-05-2021 | ADA 2021 | Conference coverage | News

AMPLITUDE-M: Improved glycemic and weight outcomes with efpeglenatide vs placebo

Treatment with efpeglenatide significantly improves glycemic control and results in weight loss for medication-naïve people with type 2 diabetes, report the AMPLITUDE-M researchers.

07-01-2021 | ADA 2021 | Conference coverage | News

Use of glucose-lowering medications remains suboptimal in people with type 2 diabetes

Findings from the DISCOVER study indicate that global use of SGLT2 inhibitors and GLP-1 receptor agonists has increased over time among people with type 2 diabetes, but remains suboptimal.

07-01-2021 | ADA 2021 | Conference coverage | News

Weight loss with semaglutide improves life quality

People with type 2 diabetes who lose weight while taking semaglutide have a parallel improvement in their health-related quality of life, particularly that related to physical exertion, report the STEP 2 investigators,

07-01-2021 | ADA 2021 | Conference coverage | News

Semaglutide 2.4 mg benefits linked to sex and weight loss

Further analyses from STEP 2 show improvements in multiple cardiometabolic risk markers with semaglutide versus placebo, and potentially greater weight loss in women than men.

06-30-2021 | ADA 2021 | Conference coverage | News

Semaglutide 2.4 mg reduces progression to type 2 diabetes

Taking semaglutide 2.4 mg can reduce the likelihood of people with overweight or obesity developing type 2 diabetes, shows further analysis of STEP 1.

06-30-2021 | Dapagliflozin | News

Dapagliflozin gains positive CHMP opinion for CKD indication

Click through to read more on this announcement

06-29-2021 | ADA 2021 | Conference coverage | Video

What do the GRADE results mean for clinical practice?

Patrick Holmes discusses whether the GRADE study answers the question of which type 2 diabetes medication should be used after metformin, and comments on the generalizability of the findings.

06-29-2021 | ADA 2021 | Conference coverage | News

Statin duration may be crucial determinant of type 2 diabetes MACE risk

The duration of statin therapy in people with type 2 diabetes may be even more important than the intensity or the achieved level of low-density lipoprotein cholesterol for preventing cardiovascular events, research suggests.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits